Dr. Rekdal is Co-founder of and served as CEO during the first 4 years of Lytix Biopharma’s formation.
After that he served as CSO and Head of R&D before he again was promoted to the position of CEO in 2019. Rekdal`s research background is within tumor immunology and his field of expertise is anticancer molecules derived from host defense peptides. Dr. Rekdal commenced his PhD on cytokines and tumor immunology in 1996, and his postdoctoral work forms the basis of Lytix Biopharma’s technology peptide platform.
Dr. Rekdal has been instrumental in establishing collaboration with several distinguished researchers and institutions and is regularly invited to give plenary lectures at international oncology, industry and partnering conferences.
Gjest Breistein, MSc, CFO
Mr. Breistein has extensive experience as an auditor and consultant. Prior to joining Lytix in 2017, he worked at PwC advising public and private companies across multiple industry sectors in capital market transactions, financing and listing processes.
Mr. Breistein is a state authorized public accountant, and holds a Masters in Applied Economics and Finance from Copenhagen Business School, as well as a Masters in Professional Accountancy from BI Norwegian School of Management.
Baldur Sveinbjørnsson, PhD, CSO
Dr. Sveinbjørnsson achieved his doctorate at the Medical Faculty of the University of Tromsø in 1998, with a focus on mechanisms and mediators behind immunomodulation of experimental tumors. Since then, Dr. Sveinbjørnsson has gained a broad experience of preclinical oncology at the University of Tromsø and Karolinska Institutet Stockholm.
Dr. Sveinbjørnsson has been involved in the research activities of Lytix Biopharma since the beginning, and has most recently led the Company’s research activities as Chief Scientific Officer.
Gry Stensrud, PhD, CTO
Dr. Stensrud has more than 20 years of experience in research, development, clinical trials, commercial manufacturing and distribution of medicinal products and medical devices, as well as extensive leadership experience in developing biotech companies.
Dr. Stensrud has held different positions at GE Healthcare and prior to joining Lytix, Dr. Stensrud was Vice President Technical Development & Operations at Photocure. Dr. Stensrud holds a degree in Pharmacy and a PhD in Pharmaceutical Technology.
Graeme Currie, PhD, CDO
Dr. Currie has over 30 years’ experience in drug development in both pharmaceutical and biotechnology companies, Dr. Currie has held many senior leadership roles at Dynavax, Regeneron Pharmaceuticals, Sepracor Inc., PDL Biopharma and Gilead Sciences. Most recently, he was Chief Development Officer of Tolerion Inc. Dr. Currie has also held key roles in the successful development of eight approved drugs.
Dr. Currie holds a PhD from Aston University in the UK.
Stephen T. Worsley, CBO
Mr. Worsley has more than 25 years experience with business development leadership in roles of increasing impact and in executing high-valuation strategic deals in the biopharmaceutical and drug discovery/development market. Most recently Mr. Worsley served as the Vice President Strategic Business Development at Redwood Biosciences/ Catalent Pharma Services. Mr. Worsley is a seasoned life sciences executive who also served roles as the CBO at Sutro Biopharma, Sr. Vice President Business Development at IndiMolecular and Vice President of Business Development at Peregrine Pharmaceutical (dba Avid Pharma Services) amongst other roles in his career.
As a business development executive, Mr. Worsley has led negotiations of transformative and award-winning technology and product partnerships for leading therapeutics companies.
Mr. Worsley holds an MBA from the University of Washington and a BS in Econ/International Finance from the University of Utah.